ClearPoint Neuro, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. ClearPoint Neuro develops and commercializes platforms for minimally invasive brain procedures, and provides products and services supporting biologics and drug-delivery development.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / prior balance |
|---|---|---|
| Total revenue | $7.639 million | $5.433 million |
| Gross profit / gross margin | $4.525 million / 59% | $3.202 million / 59% |
| Operating loss | $(4.231) million | $(5.712) million |
| Net loss | $(4.146) million; $(0.16) per share | $(5.609) million; $(0.23) per share |
| Cash used in operations | $3.840 million | $5.680 million |
| Cash and cash equivalents | $35.353 million | $23.140 million at Dec. 31, 2023 |
| Current assets / current liabilities | $47.570 million / $15.157 million | $36.172 million / $7.430 million at Dec. 31, 2023 |
| Secured convertible note | $10 million principal; 7.3% interest rate | $10 million principal at Dec. 31, 2023 |
March-quarter cash rose by $12.213 million, primarily reflecting $16.2 million of net proceeds from a March public offering of 2,653,848 shares. The company reported a $176.6 million accumulated deficit. Management stated that cash at March 31, 2024, was expected to fund operations and obligations for at least the next twelve months, based on current forecasts. The outstanding note is secured by company assets and matures in 2025.
Changes versus the prior-year quarter
- Revenue increased 41%. Biologics and drug-delivery revenue rose 61% to $4.307 million, mainly from increased services and license fees tied to new preclinical trials and consulting agreements.
- Capital equipment and software revenue increased to $1.405 million from $0.396 million, which the company attributed to more ClearPoint navigation capital/software and Prism laser placements.
- Functional neurosurgery navigation and therapy revenue declined 18% to $1.927 million. The company cited a paused brain-computer-interface co-development program, partly offset by higher product revenue.
- Gross margin remained 59%. Research and development expense declined 13% to $2.625 million following reprioritization of initiatives; sales and marketing expense increased 12% to $3.290 million, primarily due to personnel and travel costs.
- Net loss narrowed 26%, and operating cash use declined by $1.840 million.
Outlook, risks and other notable items
- No quantified revenue, earnings, or cash-flow guidance was provided. The company cautioned that Q1 results may not indicate full-year or future performance and that it may continue to incur losses.
- ClearPoint began a limited market release of its SmartFrame OR Stereotactic System in 2024; the FDA cleared the system in January 2024. The biologics and drug-delivery opportunity depends on customer research, clinical-trial outcomes, and regulatory approvals.
- Management cited risks from inflation, supply-chain disruption, labor shortages, geopolitical instability, customer spending and payment capacity, supplier concentration, product acceptance, regulation, and access to future financing. The company noted that some manufacturing components have few alternative suppliers.
- The $10 million note bears a variable rate tied to three-month SOFR, subject to a 2% floor plus a 2% margin. The filing estimates that a 1–2 percentage-point rate increase would add approximately $0.4–$0.5 million in annual interest expense above the floor.
- A pharmaceutical customer that is also a stockholder and noteholder, and whose CEO serves on the board, represented 9% of Q1 sales. Two other customers each represented 14% of sales. The noteholder relationship is therefore relevant to both customer concentration and financing.
- The company reported no material changes to its 2023 Form 10-K risk factors, no known legal proceeding expected to have a material adverse effect, and effective disclosure controls as of March 31, 2024.
Important facts for investors to verify
- Whether revenue growth, particularly biologics and drug-delivery services and equipment placements, continues in subsequent quarters.
- Cash burn, forecast assumptions behind management’s twelve-month liquidity assessment, and available financing options if growth or collections weaken.
- The 2025 maturity and variable-rate cost of the secured $10 million note, including any repayment, conversion, or refinancing developments.
- Customer concentration, related-party transactions, and the sustainability of revenue from customer-sponsored trials and programs.
- Commercial adoption of SmartFrame OR, ClearPoint systems, and Prism, alongside trial, regulatory, supplier, and market-acceptance risks.